Research graph
References from The Neuroblastoma ALK(I1250T) Mutation Is a Kinase-Dead RTK In Vitro and In Vivo. Local targets link to admitted publications; unresolved targets remain external evidence.
Identification of ALK as a major familial neuroblastoma predisposition gene
10.1038/nature07261 · 2008 · External reference
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours
10.1042/bj20081834 · 2008 · External reference
Oncogenic mutations of ALK kinase in neuroblastoma
10.1038/nature07399 · 2008 · External reference
Activating mutations in ALK provide a therapeutic target in neuroblastoma
10.1038/nature07397 · 2008 · External reference
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
10.1038/nature07398 · 2008 · External reference
Neuroblastoma: biological insights into a clinical enigma
10.1038/nrc1014 · 2003 · External reference
Anaplastic lymphoma kinase: signalling in development and disease
10.1042/bj20090387 · 2009 · External reference
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
10.1056/nejmoa1007056 · 2010 · External reference
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors
10.1056/nejmoa1007478 · 2010 · External reference
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
10.1056/nejmoa1006448 · 2010 · External reference
Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors
10.1021/bi1005514 · 2010 · External reference
Crystal structure of the anaplastic lymphoma kinase (ALK) catalytic domain
10.1042/bj20100609 · 2010 · External reference
Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells
10.1038/onc.2010.27 · 2010 · External reference
Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumour progression and unresponsiveness to therapy
10.1158/0008-5472.can-10-2366 · 2010 · External reference
Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin
10.1074/jbc.m501972200 · 2005 · External reference
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
10.1073/pnas.0609412103 · 2007 · External reference
The ligand Jelly Belly ( Jeb) activates the Drosophila Alk RTK to drive PC12 cell differentiation, but is unable to activate the mouse ALK RTK
10.1002/jez.b.21146 · 2007 · External reference
Nucleophosminanaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity
10.1128/mcb.18.12.6951 · 1998 · External reference
The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking
10.1038/onc.2010.595 · 2011 · External reference
Defining the conserved internal architecture of a protein kinase
10.1016/j.bbapap.2009.10.017 · 2010 · External reference
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF
10.1016/j.cell.2009.12.040 · 2010 · External reference
Ligand-induced transphosphorylation between different FGF receptors
10.1002/j.1460-2075.1991.tb07834.x · 1991 · External reference
Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor
10.1038/328820a0 · 1987 · External reference
Anaplastic lymphoma kinase proteins in growth control and cancer
10.1002/jcp.10472 · 2004 · External reference
Behavioral and neurochemical alterations in mice deficient in anaplastic lymphoma kinase suggest therapeutic potential for psychiatric indications
10.1038/sj.npp.1301446 · 2008 · External reference
